TN2018000306A1 - Film-coated scored tablet for the definitive treatment of baldness by inhibiting 5-alpha reductase. - Google Patents

Film-coated scored tablet for the definitive treatment of baldness by inhibiting 5-alpha reductase.

Info

Publication number
TN2018000306A1
TN2018000306A1 TNP/2018/000306A TN2018000306A TN2018000306A1 TN 2018000306 A1 TN2018000306 A1 TN 2018000306A1 TN 2018000306 A TN2018000306 A TN 2018000306A TN 2018000306 A1 TN2018000306 A1 TN 2018000306A1
Authority
TN
Tunisia
Prior art keywords
alpha reductase
baldness
treatment
film
inhibiting
Prior art date
Application number
TNP/2018/000306A
Other languages
French (fr)
Inventor
Ghidhaoui Abir
Original Assignee
Ghidhaoui Abir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ghidhaoui Abir filed Critical Ghidhaoui Abir
Priority to TNP/2018/000306A priority Critical patent/TN2018000306A1/en
Priority to PCT/TN2019/000005 priority patent/WO2020050781A1/en
Publication of TN2018000306A1 publication Critical patent/TN2018000306A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Abstract

La combinaison innovante des différents agents biologiques a permis l'élaboration d'une formule traitante pour I'Alopécie et la calvitie même à cause génétique par inhibition de la 5- alpha réductase. Ce traitement est sous forme de comprimé pelliculé sécable. Ce traitement est favorisé par rapport aux autres traitements sur le marché car il remplace la molécule de finastéride qui a des effets secondaires néfastes par une molécule synthétisée qui garde la même activité d'inhibition de la 5- alpha réductase sans des effets secondaire. Ainsi, les autres formules sur le marché sont des traitements instantanés et réversibles. Cette formule est destinée pour l'industrie pharmaceutique.The innovative combination of different biological agents has made it possible to develop a treatment formula for alopecia and baldness even from genetic causes by inhibition of 5-alpha reductase. This treatment is in the form of a scored film-coated tablet. This treatment is favored over other treatments on the market because it replaces the finasteride molecule which has harmful side effects with a synthesized molecule which keeps the same 5-alpha reductase inhibiting activity without side effects. Thus, the other formulas on the market are instant and reversible treatments. This formula is intended for the pharmaceutical industry.

TNP/2018/000306A 2018-09-03 2018-09-03 Film-coated scored tablet for the definitive treatment of baldness by inhibiting 5-alpha reductase. TN2018000306A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TNP/2018/000306A TN2018000306A1 (en) 2018-09-03 2018-09-03 Film-coated scored tablet for the definitive treatment of baldness by inhibiting 5-alpha reductase.
PCT/TN2019/000005 WO2020050781A1 (en) 2018-09-03 2019-02-13 Divisible film-coated tablet for the definitive treatment of baldness by inhibiting 5-alpha reductase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TNP/2018/000306A TN2018000306A1 (en) 2018-09-03 2018-09-03 Film-coated scored tablet for the definitive treatment of baldness by inhibiting 5-alpha reductase.

Publications (1)

Publication Number Publication Date
TN2018000306A1 true TN2018000306A1 (en) 2020-01-16

Family

ID=66476804

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2018/000306A TN2018000306A1 (en) 2018-09-03 2018-09-03 Film-coated scored tablet for the definitive treatment of baldness by inhibiting 5-alpha reductase.

Country Status (2)

Country Link
TN (1) TN2018000306A1 (en)
WO (1) WO2020050781A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39500A (en) * 2014-03-06 2017-08-15 Bionap S R L COMPOSITIONS BASED ON PLANT EXTRACTS FOR THE INHIBITION OF 5-ALPHA-REDUCTASE

Also Published As

Publication number Publication date
WO2020050781A8 (en) 2020-07-02
WO2020050781A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
MX2022015812A (en) Inhibitors of cysteine proteases and methods of use thereof.
MA52486B1 (en) Pyridazinones used as parp7 inhibitors
MX2023004923A (en) Heterocyclic compounds as immunomodulators.
MA47447B1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MX2021009246A (en) Immunomodulators, compositions and methods thereof.
MA41179A (en) PARG INHIBITOR COMPOUNDS
MA40111B1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
MA43979B1 (en) 1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders
MA42239B1 (en) New hydroxyester derivatives, their preparation process and pharmaceutical compositions containing them
MA39219B1 (en) New lrrk2 Kinase Inhibitor Compounds Used to Treat Parkinson's, Alzheimer's and Amyotrophic Lateral Sclerosis
MA30358B1 (en) QUINAZOLINES FOR THE INHIBITION OF PDK1
ATE396973T1 (en) BENZYL ETHER AND BENZYLAMINO BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MA40955B1 (en) 2-amino-6- (difluoromethyl) -5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MA32306B1 (en) Quinolines and quinoxaline derivatives as protein tyrosine kinase inhibitors
ATE517861T1 (en) BENZYL ETHER AND BENZYLAMIN COMPOUNDS AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MA54133A (en) AMINOPYRAZINE DIOL COMPOUNDS USED AS PI3K-Y INHIBITORS
MA46229B1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MA54386B1 (en) TREX1 MODULATORS
MX2022013223A (en) [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS.
MA34553B1 (en) COMBINATIONS CONTAINING SUBSTITUTED N- (2-ARYLAMINO) ARYLSULFONAMIDE
MX2021006619A (en) Tyrosine kinase inhibitors, compositions and methods there of.
MA52154B1 (en) Pharmaceutical composition for anemia
EA200601607A1 (en) SULPHONAMIDE CONNECTIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
MX2021006724A (en) Haloallylamine compounds and application thereof.
BRPI0411864A (en) combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases